BR112015011400A8 - composto, composição farmacêutica, composição de vacina, e, uso de um composto - Google Patents

composto, composição farmacêutica, composição de vacina, e, uso de um composto

Info

Publication number
BR112015011400A8
BR112015011400A8 BR112015011400A BR112015011400A BR112015011400A8 BR 112015011400 A8 BR112015011400 A8 BR 112015011400A8 BR 112015011400 A BR112015011400 A BR 112015011400A BR 112015011400 A BR112015011400 A BR 112015011400A BR 112015011400 A8 BR112015011400 A8 BR 112015011400A8
Authority
BR
Brazil
Prior art keywords
compound
integer
alkyl
value
composition
Prior art date
Application number
BR112015011400A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015011400A2 (pt
Inventor
Mary Coe Diane
Allan Smith Stephen
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112015011400A2 publication Critical patent/BR112015011400A2/pt
Publication of BR112015011400A8 publication Critical patent/BR112015011400A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112015011400A 2012-11-20 2013-11-18 composto, composição farmacêutica, composição de vacina, e, uso de um composto BR112015011400A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728390P 2012-11-20 2012-11-20
US201361774087P 2013-03-07 2013-03-07
PCT/US2013/070472 WO2014081645A1 (en) 2012-11-20 2013-11-18 Novel compounds

Publications (2)

Publication Number Publication Date
BR112015011400A2 BR112015011400A2 (pt) 2017-07-11
BR112015011400A8 true BR112015011400A8 (pt) 2019-10-01

Family

ID=50776485

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011400A BR112015011400A8 (pt) 2012-11-20 2013-11-18 composto, composição farmacêutica, composição de vacina, e, uso de um composto

Country Status (32)

Country Link
US (3) US9540383B2 (https=)
EP (1) EP2922549B1 (https=)
JP (1) JP6228223B2 (https=)
KR (1) KR20150085055A (https=)
CN (1) CN104780922B (https=)
AU (1) AU2013348218B2 (https=)
BR (1) BR112015011400A8 (https=)
CA (1) CA2892218A1 (https=)
CL (1) CL2015001342A1 (https=)
CR (1) CR20150268A (https=)
CY (1) CY1119557T1 (https=)
DK (1) DK2922549T3 (https=)
DO (1) DOP2015000121A (https=)
EA (1) EA028480B1 (https=)
ES (1) ES2639789T3 (https=)
HR (1) HRP20171150T1 (https=)
HU (1) HUE13857477T2 (https=)
IL (1) IL238800B (https=)
LT (1) LT2922549T (https=)
ME (1) ME02867B (https=)
MX (1) MX358025B (https=)
NZ (1) NZ707319A (https=)
PE (1) PE20151086A1 (https=)
PH (1) PH12015501100B1 (https=)
PL (1) PL2922549T3 (https=)
PT (1) PT2922549T (https=)
RS (1) RS56233B1 (https=)
SG (1) SG11201503282RA (https=)
SI (1) SI2922549T1 (https=)
SM (1) SMT201700378T1 (https=)
UA (1) UA114645C2 (https=)
WO (1) WO2014081645A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
HRP20181667T1 (hr) 2011-07-22 2018-12-14 Glaxosmithkline Llc Pripravak
EA026354B1 (ru) 2012-08-24 2017-03-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Пиразолопиримидиновые соединения
AU2013348217B2 (en) 2012-11-20 2016-10-06 Glaxosmithkline Llc Novel compounds
EA028480B1 (ru) 2012-11-20 2017-11-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
BR112015011439A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
HRP20210927T1 (hr) 2014-08-15 2021-09-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Spojevi pirolopirimidina koje se koriste kao agonist tlr7
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
TWI558709B (zh) * 2015-10-07 2016-11-21 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pyrrolopyrimidine ring compounds, their use and pharmaceutical compositions
UA121345C2 (uk) * 2015-11-05 2020-05-12 Чіа Тай Тяньцин Фармасьютікал Груп Ко., Лтд. 7-(тіазол-5-іл)піролопіримідин як агоніст рецептора tlr7
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
AU3176297A (en) * 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
US5985848A (en) * 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
IL150594A0 (en) 2000-01-07 2003-02-12 Ustav Ex Botan Adademie Ved Ce Purine derivatives, process for their preparation and use
AR028385A1 (es) 2000-04-28 2003-05-07 Acadia Pharm Inc Agonistas muscarinicos
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
ATE478872T1 (de) 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
US20040063658A1 (en) * 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
US6713241B2 (en) 2002-08-09 2004-03-30 Eastman Kodak Company Thermally developable emulsions and imaging materials containing binder mixture
EP1539783B1 (en) 2002-08-21 2011-04-13 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside phosphorylases and nucleosidases
MXPA05003193A (es) 2002-09-27 2005-06-08 Sumitomo Pharma Compuesto de adenina novedoso y uso del mismo.
CN1816530A (zh) 2003-07-01 2006-08-09 麦克公司 用于治疗高眼压症的眼用组合物
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
JP2007504232A (ja) 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
UY28506A1 (es) 2003-09-12 2005-04-29 Basf Ag 6-halógeno-(1,2,4)triazolo(1,5-a)pirimidinas para combatir plagas animales.
KR20060120069A (ko) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
WO2005092892A1 (ja) 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. ８−オキソアデニン化合物
US8012964B2 (en) 2004-03-26 2011-09-06 Dainippon Sumitomo Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
US20060029642A1 (en) 2004-08-03 2006-02-09 Dusan Miljkovic Methods and compositions for improved chromium complexes
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2006242920A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
NZ540160A (en) * 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
US7932257B2 (en) 2005-07-22 2011-04-26 Sunesis Pharmaceuticals, Inc. Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
RU2008110908A (ru) 2005-08-25 2009-09-27 Шеринг Корпорейшн (US) Производные имидазола в качестве функционально селективных агонистов альфа2с адренорецепторов
JP4584335B2 (ja) 2005-09-02 2010-11-17 ファイザー・インク ヒドロキシ置換１ｈ−イミダゾピリジンおよび方法
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
JPWO2007034817A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
US20090105212A1 (en) 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
JPWO2007034882A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
EP1939200A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
JPWO2007034881A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
JP2009528989A (ja) 2006-02-17 2009-08-13 ファイザー・リミテッド Ｔｌｒ７変調剤としての３−デアザプリン誘導体
EP2010505B1 (en) 2006-03-28 2012-12-05 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
GB0610666D0 (en) 2006-05-30 2006-07-05 Glaxo Group Ltd Fluid dispenser
GB2438679A (en) 2006-05-31 2007-12-05 Sra Dev Ltd Ultrasonic surgical tool having two modes of vibration
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
US8138172B2 (en) 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
US20080008682A1 (en) 2006-07-07 2008-01-10 Chong Lee S Modulators of toll-like receptor 7
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
TW200831105A (en) 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
AR065372A1 (es) 2007-02-19 2009-06-03 Smithkline Beecham Corp Derivados de purina
ES2373616T3 (es) 2007-03-19 2012-02-07 Astrazeneca Ab Compuestos de 8-oxo-adenina 9 sustituidos como moduladores del receptor de tipo toll (tlr7).
ES2457316T3 (es) 2007-03-19 2014-04-25 Astrazeneca Ab Compuestos 8-oxo-adenina 9 sustituidos como moduladores del receptor similares a toll (TLR7)
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CA2695989A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Certain nitrogen containing bicyclic chemical entities for treating viral infections
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
EP2326646B1 (en) 2008-08-11 2013-07-31 GlaxoSmithKline LLC Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
BRPI0917013A2 (pt) 2008-08-11 2016-02-16 Glaxosmithkline Llc métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
WO2010018132A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Compounds
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
BRPI0917458A2 (pt) 2008-08-11 2015-12-01 Glaxosmithkline Llc composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
CN102548999A (zh) 2009-01-20 2012-07-04 山东轩竹医药科技有限公司 含有取代的含氮稠杂环的头孢菌素衍生物
EP2454263B1 (en) * 2009-07-17 2018-06-13 Albert Einstein College of Medicine, Inc. 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
MX2012001524A (es) 2009-08-07 2012-02-29 Glaxosmithkline Biolog Sa Derivados de oxoadenina lipidada.
DK2534149T3 (da) 2010-02-10 2015-01-05 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-on-maleat
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
US20120171229A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
AU2012212323A1 (en) 2011-02-01 2013-09-12 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
WO2012106522A2 (en) * 2011-02-04 2012-08-09 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
WO2012167053A1 (en) * 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
HRP20181667T1 (hr) 2011-07-22 2018-12-14 Glaxosmithkline Llc Pripravak
EA026354B1 (ru) 2012-08-24 2017-03-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Пиразолопиримидиновые соединения
AU2013348217B2 (en) 2012-11-20 2016-10-06 Glaxosmithkline Llc Novel compounds
EA028480B1 (ru) 2012-11-20 2017-11-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
BR112015011439A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체

Also Published As

Publication number Publication date
MX358025B (es) 2018-08-02
AU2013348218A1 (en) 2015-06-04
PH12015501100B1 (en) 2017-10-06
US20150284396A1 (en) 2015-10-08
EA028480B1 (ru) 2017-11-30
CA2892218A1 (en) 2014-05-30
ES2639789T3 (es) 2017-10-30
WO2014081645A1 (en) 2014-05-30
IL238800B (en) 2018-10-31
US9540383B2 (en) 2017-01-10
US20170080085A1 (en) 2017-03-23
ME02867B (me) 2018-04-20
PH12015501100A1 (en) 2015-07-27
US20180140695A1 (en) 2018-05-24
PE20151086A1 (es) 2015-08-20
DOP2015000121A (es) 2015-11-30
EP2922549A4 (en) 2016-04-06
CY1119557T1 (el) 2018-03-07
AU2013348218B2 (en) 2016-10-13
SG11201503282RA (en) 2015-06-29
BR112015011400A2 (pt) 2017-07-11
EP2922549B1 (en) 2017-06-21
CR20150268A (es) 2015-07-01
LT2922549T (lt) 2017-09-11
RS56233B1 (sr) 2017-11-30
NZ707319A (en) 2019-09-27
CN104780922B (zh) 2016-09-07
JP2016500068A (ja) 2016-01-07
HUE13857477T2 (hu) 2018-05-28
UA114645C2 (uk) 2017-07-10
JP6228223B2 (ja) 2017-11-08
KR20150085055A (ko) 2015-07-22
HRP20171150T1 (hr) 2017-10-06
DK2922549T3 (en) 2017-09-11
US9907847B2 (en) 2018-03-06
CL2015001342A1 (es) 2015-10-02
SMT201700378T1 (it) 2017-09-07
PL2922549T3 (pl) 2017-11-30
IL238800A0 (en) 2015-06-30
MX2015006375A (es) 2015-10-05
EP2922549A1 (en) 2015-09-30
HK1208826A1 (en) 2016-03-18
PT2922549T (pt) 2017-09-01
SI2922549T1 (sl) 2017-10-30
CN104780922A (zh) 2015-07-15
EA201590684A1 (ru) 2016-03-31

Similar Documents

Publication Publication Date Title
BR112015011400A8 (pt) composto, composição farmacêutica, composição de vacina, e, uso de um composto
BR112015011447A2 (pt) composto da fórmula i, composição farmacêutica e de vacina, e, uso de um composto
BR112015011439A2 (pt) composto, composição farmacêutica, composição de vacina, e, uso de um composto
BR112015014458A8 (pt) compostos derivados de manose, seus intermediários, composição, uso e processos de preparação
BR112014026703A2 (pt) inibidores de dna-pk
EA201590189A1 (ru) Пиразолопиримидиновые соединения
EA201290631A1 (ru) Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она
BR112014007694A2 (pt) 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)óxi)naftaleno-1-il)ureias como inibidores de p38 map cinase
BR112014014184A2 (pt) triazolopiridinas substituídas e seu uso como inibidores de ttk
BR112015018751A2 (pt) derivados de piridazinona macrocíclicos
EA201100113A1 (ru) Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний
ME01604B (me) Inhibitori p38 map kinaze
BR112014029185A2 (pt) nucleosídeos de spirooxetano uracila
BR112015000615A2 (pt) purinas macrocíclicas para o tratamento de infecções virais
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112013009395A2 (pt) derivados de quinazolin-4 (3h)-ona usados como inibidores da pi3 cinase
BR112014002245A2 (pt) derivados de piridin-2(1h)-ona como inibidores de jak
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112014001801A2 (pt) indazóis
BR112014004435A2 (pt) inibidores de quinase rock
BRPI0807749B8 (pt) composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
BR112012027803A2 (pt) compostos de pirazol como inibidores de jak
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements